Search results for: 'cloud dure learning'

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules, and the rate of return has shrunk from 16% in 2011 to almost 11% in 2018. Frost & Sullivan finds that traditional solutions focused primarily on data from limited sources and rule-based computational techniques used to address the understanding of...

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules and the rate of return shrinking from 16Percentage in 2011 to almost 11Percentage in 2018. Frost & Sullivan research indicates that traditional solutions that have focused primarily on data from limited sources and rule-based computational techniqu...

27 Nov 2019  |  North America  |  Market Research

Global Contract Research Organization (CRO) Market, Forecast to 2024

Increased Technology Adoption in the Form of eClinical Solutions and Innovative Trial Designs is Expected to Transform the CRO Landscape

Infographics

×

Key Issues Addressed

Increased technology adoption in the form of eClinical solutions and innovative trial designs is expected to transform the CRO landscape. Owing to a constantly changing pharmaceutical landscape, the industry is expected to witness a moderate 4% to 5% growth in the next 5 to 7 years, to surpass $1.5 trillion by 2025. In coordination with the indust...

04 Sep 2018  |  North America  |  Market Research

Digital Transformation in the Pharmaceuticals Industry—Companies-to-Action, 2018

Value-based Care, Patient Data Digitization, and Collaborative Technology Deployment Offer Investment Opportunities

Infographics

×

Key Issues Addressed

The pharmaceutical industry today is in a state of flux as it tries to maintain a delicate balance between the need for novel blockbuster drugs and the need for improved operational efficiencies in an increasingly competitive market space. As healthcare is becoming increasingly democratized, patients are emerging as key decision makers—digitally en...

24 Jul 2020  |  North America  |  Market Research

Curative Oncology and Rare Disease Therapies Transforming the Global Biologics Market, 2020–2024

Strategic Collaborations with Specialty Bio-CDMOs will Continue to Drive Growth Opportunities in Antibody-drug Conjugates and Gene Therapies

Infographics

×

Key Issues Addressed

With this research service, Frost & Sullivans Transformational Health team provides critical insights into the global biologics industry highlighting the growth opportunities, market revenue segmentation, and technology trends influencing its growth. The global biologics market covered in this study includes 4 major segments – antibody therapies, r...

05 Feb 2021  |  North America  |  Market Research

Shifting Spotlight from Product- to Value-based Outcomes Intensifies Growth in the US Real-world Evidence IT Solutions Market

Early-stage R&D and Commercial Applications Fuel the Growth Pipeline

Infographics

×

The US healthcare industrys transition to a patient-centric model is moving rapidly with focus on outcomes and value; however, drug prices have increased and pharmaceutical research and development (R&D) productivity is at its lowest. The healthcare industry and IT solutions providers are finding real-world evidence (RWE) as a potential solution to...

The Transformational Health team at Frost & Sullivan provides critical insights into the US and EU upstream bioprocessing market, highlighting drug demand trends, installed capacity developments, market revenue forecast by various segments, competitive landscape, and key growth opportunities that currently exist or are set to develop during the for...

Despite the term patient centricity gaining currency in the industry, there is a degree of variability in a companies’ approach and strategic priorities. Frost & Sullivan sees digitization playing a critical role in transforming the clinical trial model from traditional, high-cost, and difficult-to-access centralized settings to more patient-centri...

The global life sciences industry is onto a rocking start with the surge in CEO confidence from US tax reforms, rollicking equity markets and strengthening the global economy. Healthcare digitization, democratization creating explosion in patient data, emergence of value-based reimbursement models, and healthcare consumerism shifting the risk from ...